Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51


A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.

Phillips DC, Jin S, Gregory GP, Zhang Q, Xue J, Zhao X, Chen J, Tong Y, Zhang H, Smith M, Tahir SK, Clark RF, Penning TD, Devlin JR, Shortt J, Hsi ED, Albert DH, Konopleva M, Johnstone RW, Leverson JD, Souers AJ.

Leukemia. 2019 Dec 11. doi: 10.1038/s41375-019-0652-0. [Epub ahead of print]


Effects of Chromium-Loaded Chitosan Nanoparticles on the Intestinal Electrophysiological Indices and Glucose Transporters in Broilers.

Tahir SK, Yousaf MS, Ahmad S, Shahzad MK, Khan AF, Raza M, Majeed KA, Khalid A, Zaneb H, Rabbani I, Rehman H.

Animals (Basel). 2019 Oct 17;9(10). pii: E819. doi: 10.3390/ani9100819.


Quantification of BCL-2 Family Members by Flow Cytometry.

Smith ML, Tahir SK.

Methods Mol Biol. 2019;1877:163-172. doi: 10.1007/978-1-4939-8861-7_11.


Erratum to: Sub-chronic exposure to low concentration of dibutyl phthalate affects anthropometric parameters and markers of obesity in rats.

Majeed KA, Ur Rehman H, Yousaf MS, Zaneb H, Rabbani I, Tahir SK, Rashid MA.

Environ Sci Pollut Res Int. 2017 Nov;24(32):25468. doi: 10.1007/s11356-017-0292-8.


Sub-chronic exposure to low concentration of dibutyl phthalate affects anthropometric parameters and markers of obesity in rats.

Majeed KA, Ur Rehman H, Yousaf MS, Zaneb H, Rabbani I, Tahir SK, Rashid MA.

Environ Sci Pollut Res Int. 2017 Nov;24(32):25462-25467. doi: 10.1007/s11356-017-9952-y. Epub 2017 Aug 19. Erratum in: Environ Sci Pollut Res Int. 2017 Nov;24(32):25468.


Potential mechanisms of resistance to venetoclax and strategies to circumvent it.

Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, Leverson JD, Lam LT.

BMC Cancer. 2017 Jun 2;17(1):399. doi: 10.1186/s12885-017-3383-5.


Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.

Lam LT, Lin X, Faivre EJ, Yang Z, Huang X, Wilcox DM, Bellin RJ, Jin S, Tahir SK, Mitten M, Magoc T, Bhathena A, Kati WM, Albert DH, Shen Y, Uziel T.

Mol Cancer Ther. 2017 Aug;16(8):1511-1520. doi: 10.1158/1535-7163.MCT-16-0459. Epub 2017 May 3.


Development of a flow cytometric method for quantification of BCL-2 family members in chronic lymphocytic leukemia and correlation with sensitivity to BCL-2 family inhibitors.

Smith ML, Chyla B, McKeegan E, Tahir SK.

Cytometry B Clin Cytom. 2017 Sep;92(5):331-339. doi: 10.1002/cyto.b.21383. Epub 2016 Jul 4.


Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax.

Ackler S, Oleksijew A, Chen J, Chyla BJ, Clarin J, Foster K, McGonigal T, Mishra S, Schlessinger S, Smith ML, Tahir SK, Leverson JD, Souers AJ, Boghaert ER, Hickson J.

Pharmacol Res Perspect. 2015 Oct;3(5):e00178. doi: 10.1002/prp2.178. Epub 2015 Sep 1.


Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer.

Zhang H, Xue J, Hessler P, Tahir SK, Chen J, Jin S, Souers AJ, Leverson JD, Lam LT.

Mol Cancer. 2015 Jul 2;14:126. doi: 10.1186/s12943-015-0397-y.


Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.

Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, Erickson S, Fidanze S, Fry E, Hasvold L, Jenkins GJ, Jin S, Judge RA, Kovar PJ, Madar D, Nimmer P, Park C, Petros AM, Rosenberg SH, Smith ML, Song X, Sun C, Tao ZF, Wang X, Xiao Y, Zhang H, Tse C, Leverson JD, Elmore SW, Souers AJ.

J Med Chem. 2015 May 14;58(9):4089. doi: 10.1021/acs.jmedchem.5b00616. Epub 2015 May 1. No abstract available.


Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM, Lowes KN, Kovar P, Chen J, Jin S, Smith M, Xue J, Zhang H, Oleksijew A, Magoc TJ, Vaidya KS, Albert DH, Tarrant JM, La N, Wang L, Tao ZF, Wendt MD, Sampath D, Rosenberg SH, Tse C, Huang DC, Fairbrother WJ, Elmore SW, Souers AJ.

Sci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.


Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, Erickson S, Fidanze S, Fry E, Hasvold L, Jenkins GJ, Jin S, Judge RA, Kovar PJ, Madar D, Nimmer P, Park C, Petros AM, Rosenberg SH, Smith ML, Song X, Sun C, Tao ZF, Wang X, Xiao Y, Zhang H, Tse C, Leverson JD, Elmore SW, Souers AJ.

J Med Chem. 2015 Mar 12;58(5):2180-94. doi: 10.1021/jm501258m. Epub 2015 Feb 26. Erratum in: J Med Chem. 2015 May 14;58(9):4089.


Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).

Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, Kovar P, Tanaka A, Bruncko M, Sheppard GS, Wang L, Gierke S, Kategaya L, Anderson DJ, Wong C, Eastham-Anderson J, Ludlam MJ, Sampath D, Fairbrother WJ, Wertz I, Rosenberg SH, Tse C, Elmore SW, Souers AJ.

Cell Death Dis. 2015 Jan 15;6:e1590. doi: 10.1038/cddis.2014.561.


Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, Czabotar PE, Deshayes K, Fairbrother WJ, Flygare JA, Hymowitz SG, Jin S, Judge RA, Koehler MF, Kovar PJ, Lessene G, Mitten MJ, Ndubaku CO, Nimmer P, Purkey HE, Oleksijew A, Phillips DC, Sleebs BE, Smith BJ, Smith ML, Tahir SK, Watson KG, Xiao Y, Xue J, Zhang H, Zobel K, Rosenberg SH, Tse C, Leverson JD, Elmore SW, Souers AJ.

ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. doi: 10.1021/ml5001867. eCollection 2014 Oct 9.


ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW.

Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.


The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, Shoemaker AR, Tahir SK, Zhang H, Ackler SL, Rosenberg SH, Maecker H, Sampath D, Leverson JD, Tse C, Elmore SW.

Mol Cancer Ther. 2011 Dec;10(12):2340-9. doi: 10.1158/1535-7163.MCT-11-0415. Epub 2011 Sep 13.


N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors.

Bruncko M, Tahir SK, Song X, Chen J, Ding H, Huth JR, Jin S, Judge RA, Madar DJ, Park CH, Park CM, Petros AM, Tse C, Rosenberg SH, Elmore SW.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7503-6. doi: 10.1016/j.bmcl.2010.10.010. Epub 2010 Oct 12.


Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.

Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H, Elmore SW, Kroeger PE, Tse C, Rosenberg SH, Anderson MG.

Mol Cancer Ther. 2010 Mar;9(3):545-57. doi: 10.1158/1535-7163.MCT-09-0651. Epub 2010 Feb 23.


The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.

Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, Xiao Y, Tse C, Frost DJ, Fesik SW, Rosenberg SH, Elmore SW, Shoemaker AR.

Cancer Chemother Pharmacol. 2010 Oct;66(5):869-80. doi: 10.1007/s00280-009-1232-1. Epub 2010 Jan 23.


ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.

Luo Y, Hradil VP, Frost DJ, Rosenberg SH, Gordon GB, Morgan SJ, Gagne GD, Cox BF, Tahir SK, Fox GB.

Anticancer Drugs. 2009 Jul;20(6):483-92. doi: 10.1097/CAD.0b013e32832c0acf.


Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, Marsh KC, Nimmer P, Shoemaker AR, Song X, Tahir SK, Tse C, Wang X, Wendt MD, Yang X, Zhang H, Fesik SW, Rosenberg SH, Elmore SW.

J Med Chem. 2008 Nov 13;51(21):6902-15. doi: 10.1021/jm800669s. Epub 2008 Oct 8.


Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.

Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, Oleksijew A, O'Connor JM, Wang B, Frost DJ, Bauch J, Marsh K, Tahir SK, Yang X, Tse C, Fesik SW, Rosenberg SH, Elmore SW.

Clin Cancer Res. 2008 Jun 1;14(11):3268-77. doi: 10.1158/1078-0432.CCR-07-4622.


ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW.

Cancer Res. 2008 May 1;68(9):3421-8. doi: 10.1158/0008-5472.CAN-07-5836.


Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.

Huth JR, Park C, Petros AM, Kunzer AR, Wendt MD, Wang X, Lynch CL, Mack JC, Swift KM, Judge RA, Chen J, Richardson PL, Jin S, Tahir SK, Matayoshi ED, Dorwin SA, Ladror US, Severin JM, Walter KA, Bartley DM, Fesik SW, Elmore SW, Hajduk PJ.

Chem Biol Drug Des. 2007 Jul;70(1):1-12.


Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.

Olejniczak ET, Van Sant C, Anderson MG, Wang G, Tahir SK, Sauter G, Lesniewski R, Semizarov D.

Mol Cancer Res. 2007 Apr;5(4):331-9.


Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C.

Cancer Res. 2007 Feb 1;67(3):1176-83.


Bcl-2 family proteins are essential for platelet survival.

Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, Iciek LA, Morgan SJ, Nasarre MC, Nelson R, Preusser LC, Reinhart GA, Smith ML, Rosenberg SH, Elmore SW, Tse C.

Cell Death Differ. 2007 May;14(5):943-51. Epub 2007 Jan 5.


A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, Deckwirth T, Frost DJ, Jarvis K, Joseph MK, Marsh K, McClellan W, Nellans H, Ng S, Nimmer P, O'Connor JM, Oltersdorf T, Qing W, Shen W, Stavropoulos J, Tahir SK, Wang B, Warner R, Zhang H, Fesik SW, Rosenberg SH, Elmore SW.

Cancer Res. 2006 Sep 1;66(17):8731-9.


An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH.

Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15.


A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth.

Chen Z, Merta PJ, Lin NH, Tahir SK, Kovar P, Sham HL, Zhang H.

Mol Cancer Ther. 2005 Apr;4(4):562-8.


Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative.

Tahir SK, Nukkala MA, Zielinski Mozny NA, Credo RB, Warner RB, Li Q, Woods KW, Claiborne A, Gwaltney SL 2nd, Frost DJ, Sham HL, Rosenberg SH, Ng SC.

Mol Cancer Ther. 2003 Mar;2(3):227-33.


Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.

Gwaltney SL 2nd, O'Connor SJ, Nelson LT, Sullivan GM, Imade H, Wang W, Hasvold L, Li Q, Cohen J, Gu WZ, Tahir SK, Bauch J, Marsh K, Ng SC, Frost DJ, Zhang H, Muchmore S, Jakob CG, Stoll V, Hutchins C, Rosenberg SH, Sham HL.

Bioorg Med Chem Lett. 2003 Apr 7;13(7):1363-6.


Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives.

Gwaltney SL 2nd, O'Connor SJ, Nelson LT, Sullivan GM, Imade H, Wang W, Hasvold L, Li Q, Cohen J, Gu WZ, Tahir SK, Bauch J, Marsh K, Ng SC, Frost DJ, Zhang H, Muchmore S, Jakob CG, Stoll V, Hutchins C, Rosenberg SH, Sham HL.

Bioorg Med Chem Lett. 2003 Apr 7;13(7):1359-62.


Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells.

Chen J, Jin S, Tahir SK, Zhang H, Liu X, Sarthy AV, McGonigal TP, Liu Z, Rosenberg SH, Ng SC.

J Biol Chem. 2003 Jan 3;278(1):486-90. Epub 2002 Nov 4.


Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.

Li Q, Woods KW, Claiborne A, Gwaltney SL 2nd, Barr KJ, Liu G, Gehrke L, Credo RB, Hui YH, Lee J, Warner RB, Kovar P, Nukkala MA, Zielinski NA, Tahir SK, Fitzgerald M, Kim KH, Marsh K, Frost D, Ng SC, Rosenberg S, Sham HL.

Bioorg Med Chem Lett. 2002 Feb 11;12(3):465-9.


A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.

Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, Wu-Wong JR, Frost D, Sham H, Rosenberg SH, Ng SC.

Cancer Res. 2001 Jul 15;61(14):5480-5.


Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents.

Luo Y, Rockow-Magnone SK, Joseph MK, Bradner J, Butler CC, Tahir SK, Han EK, Ng SC, Severin JM, Gubbins EJ, Reilly RM, Rueter A, Simmer RL, Holzman TF, Giranda VL.

Anticancer Res. 2001 Jan-Feb;21(1A):23-8.


Identification and characterization of A-105972, an antineoplastic agent.

Wu-Wong JR, Alder JD, Alder L, Burns DJ, Han EK, Credo B, Tahir SK, Dayton BD, Ewing PJ, Chiou WJ.

Cancer Res. 2001 Feb 15;61(4):1486-92.


Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth.

Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M, Welsh K, Reed JC, Ng SC.

Neoplasia. 2000 May-Jun;2(3):235-41.


Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines.

Han EK, Gehrke L, Tahir SK, Credo RB, Cherian SP, Sham H, Rosenberg SH, Ng S.

Eur J Cancer. 2000 Aug;36(12):1565-71. Erratum in: Eur J Cancer. 2007 Apr;43(6):1108. Kyu-Ho Han, E [corrected to Han, E K].


Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin.

Tahir SK, Kovar P, Rosenberg SH, Ng SC.

Biotechniques. 2000 Jul;29(1):156-60.


Modulation of paclitaxel resistance by annexin IV in human cancer cell lines.

Han EK, Tahir SK, Cherian SP, Collins N, Ng SC.

Br J Cancer. 2000 Jul;83(1):83-8.


Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue.

Tahir SK, Gu WZ, Zhang HC, Leal J, Lee JY, Kovar P, Saeed B, Cherian SP, Devine E, Cohen J, Warner R, Wang YC, Stout D, Arendsen DL, Rosenberg S, Ng SC.

Eur J Cancer. 2000 Jun;36(9):1161-70.


Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo.

Gu WZ, Tahir SK, Wang YC, Zhang HC, Cherian SP, O'Connor S, Leal JA, Rosenberg SH, Ng SC.

Eur J Cancer. 1999 Sep;35(9):1394-401.


Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines.

Gu WZ, Chen Z, Tahir SK, Rosenberg SH, Ng SC.

Anticancer Drugs. 1999 Nov;10(10):895-901.


Cannabinoid enantiomer action on the cytoarchitecture.

Wilson RG Jr, Tahir SK, Mechoulam R, Zimmerman S, Zimmerman AM.

Cell Biol Int. 1996 Feb;20(2):147-57.


Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells.

Tahir SK, Trogadis JE, Stevens JK, Zimmerman AM.

Biochem Cell Biol. 1992 Oct-Nov;70(10-11):1159-73.


Influence of marihuana on cellular structures and biochemical activities.

Tahir SK, Zimmerman AM.

Pharmacol Biochem Behav. 1991 Nov;40(3):617-23. Review.


The effects of delta-9-tetrahydrocannabinol on actin microfilaments.

Kiosses BW, Tahir SK, Kalnins VI, Zimmerman AM.

Cytobios. 1990;63(252):23-9.


Supplemental Content

Loading ...
Support Center